With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

DS-9606 was supposed to be the first antibody-drug conjugate in Daiichi Sankyo’s line of anti-cancer assets to use a modified pyrrolobenzodiazepine payload.

While CagriSema bested Novo Nordisk's Wegovy on blood sugar control in a late-stage trial, the next-gen weight loss drug still has not met the pharma's 25% weight loss goal.

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in ...

Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.

Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.

The program will allow for frequent communication with the FDA, giving manufacturers timely input and guidance regarding the ...

A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data ...

Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.